

# WESTMEAD RESEARCH HUB INNOVATION PIPELINE

April 2017

Indication	Description	Lead / Owner	IP Status	Status	Discovery	in vitro POC	in vivo POC	Lead optimisation	pre-clinical	Clinical
<b>THERAPUETIC OR DELIVERY</b>										
Ventricular Arrhythmia	AAV Based gene therapy for Ventricular Arrhythmia	WSLHD, USYD, WIMR	PCT	Available	x	x	x			
HSCT transplantation	Adoptive T-cell therapy targeting fungal infections post-HSCT	WSLHD, USYD, WIMR	PCT	Available	x	x	x	x	x	
HSCT transplantation	Methods & compositions for Adoptive T-cell therapy	WSLHD, USYD, WIMR	Prov							
Multiple Myeloma	CAR T-Cell therapy	WSLHD, USYD, WIMR, CMRI	PCT	Partnered	x	x	x	x		
Herpes Simplex virus	Candidate epitope candidates as vaccine for Herpes Simplex Virus	WSLHD, USYD	Nat Phase	Available	x	x				
AMD	AAV based gene therapy for Age Related Macular Degeneration	Cambridge CMRI, SCHN,	Provisional	Partnered	x					
Gene delivery	Stable gene transfer system to proliferating cells	CMRI, SCHN	PCT	Available	x	x	x			
Gene delivery	AAV Mini-promotor for efficient delivery of large genes to liver cells	CMRI, SCHN	PCT	Available	x	x	x			
Gene delivery	Novel AAV capsid peptide for gene delivery	CMRI, SCHN	Provisional	Available	x					
Kidney Disease	Use of Dynamin Ring Stabilisers as therapeutic for kidney disease	CMRI	Nat Phase	Available	x	x	x			
Cancer	Dynamin inhibitor co-treatment with a monoclonal antibody	CMRI, UQ, UoN	Provisional	Available	x	x				
<b>MEDICAL DEVICES</b>										
Name	Description	Owner	IP Status	Status	Concept	POC	Prototype	Product Validation	Registration	Sales
SyMaxys	Paediatric implant for osteogenesis imperfecta	SCHN	Nat Phase	Partnered	x	x	x	x		
Rifle Rod	Implantable device for correcting rotational deformities in children	SCHN	PCT	Partnered	x	x	x	x		
Epic Plate	Implantable device for correcting angular deformities in children	SCHN	PCT	Partnered	x	x	x			
PISTOL	Resorbable bone stent technology for fracture healing	SCHN	Nat Phase	Partnered	x	x	x			
Sure-Lock	Screw retention mechanism for orthopaedic screw drivers/handles	SCHN	PCT	Available	x	x	x			
RDN Catheter	Microwave catheter for renal artery denervation	USYD, WSLHD	PCT	Available	x	x	x			
Monitoring catheter	Catheter for monitoring and early detection of pericardial effusion	WSLHD	Provisional	Available	x	x	x			

## Contacts

**Western Sydney Local Health District (WSLHD) & Sydney Children's Hospital Network (SCHN)**  
David Markwell  
IP and Commercialisation Manager  
E: David.Markwell@health.nsw.gov.au  
P: +61 439 875 825

**University of Sydney (USYD) & Westmead Institute for Medical Research (WIMR)**  
Dr Nadia Pece-Barbara  
Commercial Theme Leader, Westmead Precinct  
E: nadia.pece-barbara@sydney.edu.au  
P: +61 417 168 561

**Children's Medical Research Institute (CMRI)**  
Julia Hill  
Head of Commercialisation  
E: jhill@cmri.org.au  
P: +61 2 8865 2839

# WESTMEAD RESEARCH HUB INNOVATION PIPELINE

Name	Description	Owner	IP Status	Status	Concept	POC	Prototype	Product Validation	Registration	Sales
<b>DIAGNOSTICS</b>										
Fibrosis progression test	Genetic test for predicting rapid liver fibrosis progression	WSLHD, USYD	Nat Phase	Available	x	x	x	x		
Clusterin Diagnostic	Protein based diagnostic for allograft rejection	Mt Sanai, WSLHD, WIMR	Nat Phase	Available	x	x				
Motion correction software	Data-driven method for rigid motion correction in CT imaging	USYD, WSLHD	Nat Phase	Available	x	x				
ALT Assay (Cancer)	Alternative Lengthening of Telomeres (ALT) activity in cells	CMRI	Nat Phase	Available (non-excl)	x	x	x	x		
Telomere length (Cancer)	Algorithm for measurement of telomere length	CMRI	In Progress	Available	x					

## Westmead Research Hub

Westmead Research Hub offers a full spectrum of medical research from basic research to translational and clinical research, and population health studies. It has one of the largest concentrations of biomedical, scientific and healthcare focused minds in Australia.

Westmead is home to over 1,100 full-time equivalent (FTE) research staff, across four major institutes and numerous research centres, groups and networks. The majority of these (700) are full-time researchers, including 170 leading clinician-scientists, with the remainder being research support staff.

In 2015 Westmead researchers were awarded over \$79 million in Category 1 public medical research grants, and researchers at Westmead achieved a grant writing success rate of 22%, compared to a publicised national success rate of 14%.

## Selected Unique Capabilities

- Sydney Centre for Cell and Gene Therapy, a GMP compliant facility supporting Pancreas Islet Transplantation, T cell adoptive immunotherapy and Gene Therapy
- ProCan™ Industrial scale proteomics for diagnostic development and target discovery
- Cell Bank Australia, Cell bank repository, including an exclusive partnership with ECACC, and cell line testing services
- EPIC Lab: 3D Design and printing of novel orthopaedic implants for children with bone malformations or fractures.
- Vector and Genome Engineering Facility, state of the art technology to create vectors for the delivery of gene therapies into diseased tissue, and development of this technology.

## Contacts

**Western Sydney Local Health District (WSLHD) & Sydney Children's Hospital Network (SCHN)**  
David Markwell

IP and Commercialisation Manager  
E: David.Markwell@health.nsw.gov.au  
P: +61 439 875 825

**University of Sydney (USYD) & Westmead Institute for Medical Research (WIMR)**

Dr Nadia Pece-Barbara  
Commercial Theme Leader, Westmead Precinct  
E: nadia.pece-barbara@sydney.edu.au  
P: +61 417 168 561

**Children's Medical Research Institute (CMRI)**

Julia Hill  
Head of Commercialisation  
E: jhill@cmri.org.au  
P: +61 2 8865 2839